Company: SUPN
Filing Date: 2025-07-31
Form Type: 8-K
Source: 0001104659-25-072506
Chunk: 3

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 8-K
Item: Item 9.01
Chunk 3
---
Item 9.01      Financial Statements and Exhibits.  

(d)            Exhibits

Exhibit 2.1* - Agreement and Plan of Merger, dated as of June 13, 2025, by and among Supernus Pharmaceuticals, Inc., Sage Therapeutics, Inc. and Saphire, Inc (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by Supernus Pharmaceuticals, Inc. on June 16, 2025).

Exhibit 10.1 - Contingent Value Rights Agreement, dated as of July 30, 2025, by and among Supernus Pharmaceuticals, Inc. and Equiniti Trust Company, LLC

Exhibit 99.1 - Press Release of Supernus Pharmaceuticals, Inc. dated July 31, 2025.

Exhibit 104 - The cover page from
this Current Report on Form 8-K, formatted in Inline XBRL.

Certain financial statements required by Item 9.01 of Form 8-K
are not yet available and will be filed by amendment to this Current Report on Form 8-K no later than 71 calendar days after the
date that this Current Report on Form 8-K is required to be filed.

* Scheduled omitted pursuant to Item 601 of Regulation S-K.
Supernus agrees to furnish supplementally a copy of any omitted schedule to the SEC upon request.

SIGNATURES